-
1
-
-
75149128665
-
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits
-
Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
-
(2010)
Diabetes Care
, vol.33
, pp. 428-433
-
-
Drucker, D.J.1
Sherman, S.I.2
Gorelick, F.S.3
Bergenstal, R.M.4
Sherwin, R.S.5
Buse, J.B.6
-
2
-
-
82855179439
-
Tolerability of dipeptidyl peptidase-4 inhibitors: a review
-
Richard K.R., Shelburne J.S., Kirk J.K. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011, 33:1609-1629.
-
(2011)
Clin Ther
, vol.33
, pp. 1609-1629
-
-
Richard, K.R.1
Shelburne, J.S.2
Kirk, J.K.3
-
3
-
-
83455210130
-
Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes
-
Forst T., Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother 2012, 13:101-110.
-
(2012)
Expert Opin Pharmacother
, vol.13
, pp. 101-110
-
-
Forst, T.1
Pfützner, A.2
-
4
-
-
84858011452
-
Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus
-
Neumiller J.J. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2012, 46:358-367.
-
(2012)
Ann Pharmacother
, vol.46
, pp. 358-367
-
-
Neumiller, J.J.1
-
5
-
-
84857917241
-
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux
-
Fuchs H., Runge F., Held H.D. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci 2012, 45:533-538.
-
(2012)
Eur J Pharm Sci
, vol.45
, pp. 533-538
-
-
Fuchs, H.1
Runge, F.2
Held, H.D.3
-
6
-
-
84861693987
-
Pharmacokinetics of linagliptin in subjects with hepatic impairment
-
Graefe-Mody U., Rose P., Retlich S., Ring A., Waldhauser L., Cinca R., et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012, 74:75-85.
-
(2012)
Br J Clin Pharmacol
, vol.74
, pp. 75-85
-
-
Graefe-Mody, U.1
Rose, P.2
Retlich, S.3
Ring, A.4
Waldhauser, L.5
Cinca, R.6
-
7
-
-
84893745980
-
-
Package insert with linagliptin drug information.
-
Package insert with linagliptin drug information. http://www.info.pmda.go.jp/go/pack/3969014F1024_1_05.
-
-
-
-
8
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
Sandor, P.4
Ruiz, I.5
Roberts, E.A.6
-
9
-
-
33846618263
-
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists
-
Andrade R.J., Robles M., Fernández-Castañer A., López-Ortega S., López-Vega M.C., Lucena M.I. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol 2007, 13:329-340.
-
(2007)
World J. Gastroenterol
, vol.13
, pp. 329-340
-
-
Andrade, R.J.1
Robles, M.2
Fernández-Castañer, A.3
López-Ortega, S.4
López-Vega, M.C.5
Lucena, M.I.6
-
10
-
-
0027448634
-
Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge
-
Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-1336.
-
(1993)
J Clin Epidemiol
, vol.46
, pp. 1331-1336
-
-
Benichou, C.1
Danan, G.2
Flahault, A.3
-
11
-
-
84876523499
-
Dipeptidyl peptidase-4: a key player in chronic liver disease
-
Itou M., Kawaguchi T., Taniguchi E., Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013, 19:2298-2306.
-
(2013)
World J Gastroenterol
, vol.19
, pp. 2298-2306
-
-
Itou, M.1
Kawaguchi, T.2
Taniguchi, E.3
Sata, M.4
-
12
-
-
75449112589
-
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
-
Lammert C., Bjornsson E., Niklasson A., Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
-
(2010)
Hepatology
, vol.51
, pp. 615-620
-
-
Lammert, C.1
Bjornsson, E.2
Niklasson, A.3
Chalasani, N.4
-
13
-
-
76149095920
-
Elevated hepatic enzymes potentially associated with sitagliptin
-
Gross B.N., Cross L.B., Foard J., Wood Y. Elevated hepatic enzymes potentially associated with sitagliptin. Ann Pharmacother 2010, 44:394-395.
-
(2010)
Ann Pharmacother
, vol.44
, pp. 394-395
-
-
Gross, B.N.1
Cross, L.B.2
Foard, J.3
Wood, Y.4
-
14
-
-
79955618322
-
A case of drug-induced hepatic injury associated with sitagliptin
-
Toyoda-Akui M., Yokomori H., Kaneko F., Shimizu Y., Takeuchi H., Tahara K., et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med 2011, 50:1015-1020.
-
(2011)
Intern Med
, vol.50
, pp. 1015-1020
-
-
Toyoda-Akui, M.1
Yokomori, H.2
Kaneko, F.3
Shimizu, Y.4
Takeuchi, H.5
Tahara, K.6
|